Physician profile
David Aizuss
NPI 1346221728
$3,607.61
in general payments reported to CMS, 2019-2025
22 companies · $352 in 2025
The $352 reported for 2025 was less than what a typical Ophthalmology provider received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,350 · 2020: $58.46 · 2021: $275 · 2022: $937 · 2023: $215 · 2024: $420 · 2025: $352.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $987.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $987.28 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Johnson & Johnson Surgical Vision, INC. | $753.97 | 2019-2022 | |
| Alcon Vision LLC | $718.53 | 2019-2025 | Clareon Panoptix Pro, Tryptyr, Clareon |
| Glaukos Corporation | $463.85 | 2019-2024 | Idose |
| Sun Pharmaceutical Industries INC. | $270.90 | 2019-2025 | |
| Optos, INC. | $256.42 | 2019-2022 | |
| Abbvie INC. | $238.16 | 2022-2025 | Botox, Ubrelvy |
| Eyepoint US, INC. | $173.12 | 2019 | |
| Rxsight INC | $140.58 | 2022-2023 | Rxsight Light Delivery Device (Ldd), Rxsight Injector Handpiece, Rxsight Contact Lens |
| Novartis Pharmaceuticals Corporation | $105.28 | 2022-2023 | |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $94.03 | 2019-2021 | |
| Harrow Eye, LLC | $88.15 | 2025 | Vevye |
| Carl Zeiss Meditec USA, INC. | $59.56 | 2022 | |
| Nova Eye, INC. | $47.15 | 2024 | |
| Boston Scientific Corporation | $35.71 | 2022 | |
| Tarsus Pharmaceuticals, INC. | $33.73 | 2025 | Xdemvy |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $26.19 | 2024 | Izervay |
| Shire North American Group INC | $25.57 | 2019 | |
| Aerie Pharmaceuticals, INC. | $18.38 | 2019 | |
| Eyevance Pharmaceuticals LLC | $14.93 | 2022 | |
| Biotissue Holdings INC. | $14.71 | 2019 | |
| Allergan, INC. | $14.49 | 2022 | |
| Bausch & Lomb Americas INC. | $14.20 | 2024 | Miebo |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Aizuss listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.